These findings not only give insight into the pathophysiology of the disease but also indicate possible use of systemic BDNF levels as a biomarker for monitoring the onset and progression of neurodegenerative diseases such as glaucoma and Alzheimer disease. This evidence concerns the gene BDNF and early-onset autosomal dominant Alzheimer disease.